Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam preclinical-clinical program

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 232-237

  Manusama, Eric R ^a   Nooijen, Peet T G A ^a   Ten Hagen, Timo L M ^a   Van Der Veen, Alex H ^a   De Vries, Mark W R ^a   De Wilt, Johannes H W ^a   Van Ijken, Marc G ^a   Marquet, Richard L ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Animal disease models; Extremities; Liposomes; Liver neoplasms; Melanoma; Rats; Regional perfusion; Sarcoma; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CYTOPATHOGENIC EFFECT; HEALTH PROGRAM; LIMB PERFUSION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SARCOMA; WHOLE BODY RADIATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DRUG CARRIERS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; LIPOSOMES; MELPHALAN; NITRIC OXIDE; PERFUSION; RATS; SWINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031942952     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<232::AID-SSU7>3.0.CO;2-9     Document Type: Review

References (52)

1. Liénard D, Ewalenko P, Delmotte JJ, et al: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:50-62.
2. Lejeune FJ, Liénard D, Leyvraz S, Mirimanoff RO: Regional therapy of melanoma [Review]. Eur J Cancer 1993;29A:606-612.
3. Eggermont AMM, Liénard D, Schraffordt Koops H, et al: High dose TNFα in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases and unresectable sarcomas. Reg Cancer Treat 1995;8:32-36.
4. Liénard D, Eggermont AM, Schraffordt Koops H, et al: Isolated limb perfusion for treatment of locally advanced melanoma [Abstract]. Eur Cytokine Netw 1996;7:299.
5. Fraker DL: Regional perfusion of the limb and liver: clinical results and mechanisms of action [Abstract]. Eur Cytokine Netw 1996;7:286.
6. Eggermont AM: Treatment of melanoma in-transit metastases confined to the limb. Cancer Surveys 1996;26:335-349.
7. Eggermont AM, Schraffordt Koops H, Lienard D, et al: Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with IFN-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653-2665.
8. Eggermont AM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-765.
9. Eggermont AM, Schraffordt Koops H, Lienard D, et al: Destruction of tumor associated vessels by isolated limb perfusion with tumor necrosis factor α: angiographic observations in sarcoma patients [Abstract]. Eur J Surg Oncol 1994;20:403.
10. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcomas treated by single dose TNFα + melphalan isolated limb perfusion. NMR Biomed 1995;8:215-224.
11. Engel T, Vaupel P: Acute effects of tumor necrosis factor-alpha or lymphotoxin on oxygenation and bioenergetic status in experimental tumors. Adv Exp Med Biol 1994;345:501-508.
12. Kluge M, Elger B, Engel T, et al: Acute effects of tumor necrosis factor alpha or lymphotoxin on global blood flow, laser Doppler flux, and bioenergetic status of subcutaneous rodent tumors. Cancer Res 1992;52:2167-2173.
13. Renard N, Liénard D, Lespagnard L, et al: Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNFα). Int J Cancer 1994;57:656-663.
14. Renard N, Nooijen PT, Schalkwijk L, et al: VWF release and platelet aggregation in human melanoma after perfusion with TNFα. J Pathol 1995;176:279-287.
15. Nooijen PT, Eggermont AM, Verbeek MM, et al: Transient induction of E-selectin expression following TNFα-based isolated limb perfusion in melanoma and sarcoma patients is not tumor specific. J Immunother 1996;19:33-44.
16. Nawroth P, Handley D, Matsueda G, et al: Tumor necrosis factor cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. 1988;J Exp Med 168:637-647.
17. Kort WJ, Zondervan PE, Hulsman LO, et al: Incidence of spontaneous tumors in a group of retired breeder female Brown Norway rats. J Natl Cancer Inst 1984;72:709-713.
18. Barendsen, GW, Janse HC: Differences in effectiveness of combined treatments with ionizing radiation and vinblastine, evaluated for experimental sarcomas and squamous cell carcinomas in rats. Int J Radiat Oncol Biol Phys 1978;4:95-102.
19. Manusama ER, Durante NM, Marquet RL, Eggermont AM: Ischemia promotes the antitumor effect of tumor necrosis factor alpha (TNFα) in isolated limb perfusion in the rat. Reg Cancer Treat 1994;7:155-159.
20. Manusama ER, Nooijen PT, Stavast J, et al: Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat. Br J Surg 1996;83:551-555.
21. Manusama ER, Stavast J, Durante NM, et al: Isolated limb perfusion with TNFα and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996;22:152-157.
22. Posner M, Liénard D, Lejeune FJ, et al: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor (TNF) alone for metastatic intransit melanoma [Abstract]. Proc Am Soc Clin Oncol 1994;13:1351.
23. Asher AL, Mule JJ, Reichert CM, et al: Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-974.
24. Nooijen PT, Manusama ER, Schalkwijk L, et al: Synergistic effects of TNFα and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996;74:1908-1915.
25. Kachel DL, Martin WJ 2nd: Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J Pharmacol Exp Ther 1994;268:42-46.
26. Lazo JS: Endothelial injury caused by antineoplastic agents [Review]. Biochem Pharmacol 1986;35:1919-1923.
27. Eskey CJ, Koretsky AP, Domach MM, et al: 2H-Nuclear magnetic resonance imaging of tumor blood flow: spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res 1992;52:6010-6019.
28. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
29. Jain RK: Delivery of therapeutic agents to solid tumors: role of vascular and interstitial physiology [Abstract]. Proc Am Assoc Cancer Res 1994;35:661.
30. Kristensen CA, Nozue M, Boucher Y, et al: Reduction of interstitial fluid pressure after TNF-α treatment of three human melanoma xenografts. Br J Cancer 1996;74:533-536.
31. Manusama ER, Stavast J, Marquet RL, Eggermont AM: Total body irradiation (TBI) attenuates antitumor effects of TNFα in isolated limb perfusions (ILP) in the rat [Abstract]. Eur J Surg Res 1995;27(Supp 1):110.
32. van de Merwe SA, van den Berg AP, Kroon BB, et al: Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 1993;9:205-217
33. Stephens FO: Induction (neo-adjuvant) chemotherapy: systemic and arterial delivery techniques and their clinical applications [Review]. Aust N Z J Surg 1995;65:699-707.
34. Averbach AM, Stuart OA, Sugarbaker TA, et al: Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers. Ann Surg Oncol 1995;2:325-331.
35. de Kossodo S, Moore R, Gschmeissner S, et al: Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br J Cancer 1995;72:1165-1172.
36. Thomsen LL, Miles DW, Happerfield L, et al: Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41-44.
37. Andrade SP, Hart IR, Piper PJ: Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992;107:1092-1095.
38. Hansson GK, Geng YJ, Holm J, et al: Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994;180:733-738.
39. Manusama ER, Durante NM, Marquat RL, Eggermont AM: Nitric oxide inhibition enhances the anti tumor effect of TNFα in an isolated limb perfusion (ILP) model in the rat [Abstract]. Eur J Surg Res 1995;27(Suppl 1):79.
40. Southan GJ, Szabo C, Thiemermann C: Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 1995;114:510-516.
41. Progrebniak HW, Witt CJ, Terrill R, et al: Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 1994;57:1477-1483.
42. Fraker DL, Alexander HR, Thom AK: Use of tumor necrosis factor in isolated hepatic perfusion [Review]. Circ Shock 1994; 44:45-50.
43. Borel Rinkes IH, de Vries MR, Jonker AM, et al: Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 1997;75:1447-I453.
44. van de Veen AH, Manusama ER, Kampen van CA, et al: Tumor necrosis factor-α (TNFα) in isolated kidney perfusions in rats: toxicity and antitumor effects. Eur J Surg Oncol 1994;20:404-405.
45. de Vries MR, Borel Rinkes IH, Hack CE, et al: Isolated hepatic perfusion with TNF-α and melphalan: local and systemic effects on secondary cytokine release, coagulation and fibrinolysis [Abstract]. Eur J Surg Res 1995;27(Suppl 1):109.
46. de Vries MR, Borel Rinkes IHM, Buurman WA, et al: Soluble TNFα receptor induction by isolated hepatic perfusion with TNF-α and melphalan [Abstract]. Eur J Surg Res 1995; 27(Suppl 1):108.
47. Kuppen PJ, Jonges LE, van de Velde CJ, et al: Liver and tumour tissue concentrations of TNF-α in cancer patients treated with TNF-α and melphalan by isolated liver perfusion. Br J Cancer 1997;75:1497-1500.
48. Kahky MP, Daniel CO, Cruz AB, Gaskill HV 3rd: Portal infusion of tumor necrosis factor increases mortality in rats. J Surg Res 1990;49:138-145.
49. Eggermont AM, Manusama ER, ten Hagen TL: Regional application of TNFα in the treatment of cancer [Review]. J Inflammation 1996;47:104-113.
50. Jain RK: Transport of molecules across tumor vasculature [Review]. Cancer Metastasis Rev 1987;6:559-593.
51. van derVeen AH, ten Hagen TL, Marquet RL, Eggermont AM: Treatment of solid limb tumors with liposome encapsulated tumor necrosis factor-α in the rat [Abstract]. Proc Am Assoc Cancer Res 1996;37:483.
52. ten Hagen TL, Eggermont AM: A rat extremity soft tissue sarcoma model for the study of systemic treatment with Stealth® liposome-encapsulated tumor necrosis factor-α and cytotoxic agents. Adv Drug Del Rev 1997;24:245-256.